CompletedPhase 2NCT00325507
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Oxford BioMedica
- Principal Investigator
- Robert J Amato, MDThe Methodist Hospital Research Institute
- Intervention
- TroVax(biological)
- Enrollment
- 25 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2008
Study locations (1)
- The Methodist Hospital, Houston, Texas, United States
Collaborators
The Methodist Hospital Research Institute · ORION Clinical Services
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00325507 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07402109CBCT Guided Markerless SBRT for Renal Cell CancerErasmus Medical Center
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
See all trials for Acquired cystic disease-associated renal cell carcinoma →